GlobeNewswire: Myovant Sciences, Inc. Contains the last 10 of 127 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T07:08:19ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/01/26/2596463/0/en/Myovant-Sciences-Announces-Corporate-Updates-and-Financial-Results-for-Third-Fiscal-Quarter-2022.html?f=22&fvtc=4&fvtv=54815Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 20222023-01-26T21:05:00Z<![CDATA[BASEL, Switzerland, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and men through purpose-driven science, empowering medicines, and transformative advocacy, today announced financial results for the third quarter of fiscal year 2022 and provided other corporate updates.]]>https://www.globenewswire.com/news-release/2022/11/16/2557693/0/en/Myovant-Sciences-Announces-New-Employment-Inducement-Grants-Under-NYSE-Rule-303A-08.html?f=22&fvtc=4&fvtv=54815Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.082022-11-16T21:45:00Z<![CDATA[BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that it approved equity awards for 18 new employees with a grant date of November 15, 2022 pursuant to Myovant’s 2020 Inducement Plan. The equity awards were granted to the employees joining Myovant in accordance with NYSE’s Listed Company Manual Rule 303A.08.]]>https://www.globenewswire.com/news-release/2022/11/16/2556993/0/en/Myovant-Sciences-Appoints-Ann-Tomlin-as-Senior-Vice-President-of-Human-Resources.html?f=22&fvtc=4&fvtv=54815Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human Resources2022-11-16T11:45:00Z<![CDATA[BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced the appointment of Ann Tomlin as Senior Vice President of Human Resources. Beginning November 28, Ms. Tomlin will be responsible for developing talent solutions and human resources strategies across Myovant’s global functions. She will serve as a member of the Executive Committee and will report to David Marek, Myovant’s Chief Executive Officer.]]>https://www.globenewswire.com/news-release/2022/10/26/2541832/0/en/Myovant-Sciences-Announces-Corporate-Updates-and-Financial-Results-for-Second-Fiscal-Quarter-2022.html?f=22&fvtc=4&fvtv=54815Myovant Sciences Announces Corporate Updates and Financial Results for Second Fiscal Quarter 20222022-10-26T12:30:00Z<![CDATA[BASEL, Switzerland, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced financial results for the second quarter of fiscal year 2022 and provided other corporate updates.]]>https://www.globenewswire.com/news-release/2022/10/24/2540378/0/en/Myovant-Sciences-Cancels-Second-Quarter-Earnings-Conference-Call.html?f=22&fvtc=4&fvtv=54815Myovant Sciences Cancels Second Quarter Earnings Conference Call2022-10-24T20:30:00Z<![CDATA[BASEL, Switzerland, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) (“Myovant”) today announced the cancellation of its earnings conference call for the quarter ended September 30, 2022 that had originally been scheduled for October 26, 2022 at 5:00 p.m. Eastern Time. The call is being cancelled due to the announcement of the pending merger with Sumitovant Biopharma Ltd.]]>https://www.globenewswire.com/news-release/2022/10/24/2539626/0/en/Sumitovant-Biopharma-Sumitomo-Pharma-and-Myovant-Sciences-Enter-into-Definitive-Agreement.html?f=22&fvtc=4&fvtv=54815Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement2022-10-24T03:36:52Z<![CDATA[Sumitovant Biopharma to Acquire all Outstanding Shares of Myovant for $27 Per Share in Cash]]>https://www.globenewswire.com/news-release/2022/10/18/2536936/0/en/Myovant-Sciences-Announces-New-Employment-Inducement-Grants-Under-NYSE-Rule-303A-08.html?f=22&fvtc=4&fvtv=54815Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.082022-10-18T20:30:00Z<![CDATA[BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that it approved equity awards for 10 new employees with a grant date of October 17, 2022 pursuant to Myovant’s 2020 Inducement Plan. The equity awards were granted to the employees joining Myovant in accordance with NYSE’s Listed Company Manual Rule 303A.08.]]>https://www.globenewswire.com/news-release/2022/10/14/2534747/0/en/CORRECTION-Myovant-Sciences-Inc.html?f=22&fvtc=4&fvtv=54815CORRECTION -- Myovant Sciences, Inc.2022-10-14T14:02:14Z<![CDATA[BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- In a release issued under the headline "Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m." earlier today by Myovant Sciences, Inc. (NYSE: MYOV), please note that the date of the conference call was omitted from the headline. The corrected release follows:]]>https://www.globenewswire.com/news-release/2022/10/14/2534515/0/en/Myovant-Sciences-to-Host-Second-Fiscal-Quarter-2022-Earnings-Conference-Call-at-5-00-p-m.html?f=22&fvtc=4&fvtv=54815Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m.2022-10-14T10:45:00Z<![CDATA[BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter, ended September 30, 2022. The webcast and conference call will be held at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on October 26, 2022.]]>https://www.globenewswire.com/news-release/2022/10/02/2526430/0/en/Myovant-Sciences-Special-Committee-of-Board-Confirms-Receipt-of-Preliminary-Non-binding-Proposal-from-Sumitovant-Biopharma-and-Sumitomo-Pharma-to-Acquire-Remaining-Shares.html?f=22&fvtc=4&fvtv=54815Myovant Sciences Special Committee of Board Confirms Receipt of Preliminary, Non-binding Proposal from Sumitovant Biopharma and Sumitomo Pharma to Acquire Remaining Shares2022-10-02T23:36:11Z<![CDATA[BASEL, Switzerland, Oct. 02, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences Ltd. (NYSE: MYOV) (the “Company”) confirmed today that it has received a preliminary, non-binding proposal (the “Proposal”) from Sumitovant Biopharma Ltd. (“Sumitovant”) and Sumitomo Pharma Co., Ltd. (collectively with Sumitovant, “Sumitomo”) to acquire the remaining shares of the Company that Sumitovant does not currently hold, for a price of $22.75 per share in cash. Sumitovant currently holds approximately 52% of the outstanding shares of the Company.]]>